---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-149714"
form_type: "8-K"
ticker: "GENC"
cik: "0000064472"
company_name: "GENCOR INDUSTRIES INC"
filed_at: "2025-06-27T23:59:59+00:00"
generated_at: "2026-05-18T16:59:29.346542+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Gencor receives NYSE American extension to Aug 19, 2025 to file delinquent reports

## Summary
- NYSE accepted extension request; new cure deadline August 19, 2025.
- Delinquent reports: 10-K for FY ended Sep 30, 2024, and 10-Qs for Dec 31, 2024 and Mar 31, 2025.
- Company expects to file 10-K within initial six-month period and 10-Qs by Aug 19, 2025.
- Failure to make progress or file by Dec 30, 2025 could result in delisting.

## SEC filing metadata
- accession: 0001193125-25-149714
- form_type: 8-K
- ticker: GENC
- cik: 0000064472
- company_name: GENCOR INDUSTRIES INC
- filed_at: 2025-06-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64472/000119312525149714/0001193125-25-149714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64472/000119312525149714/d68871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-149714
- JSON: https://secwatch.observer/filing/0001193125-25-149714.json
- Plain text: https://secwatch.observer/filing/0001193125-25-149714.txt

## Key facts
- Listing & Compliance Notices
  GENCOR INDUSTRIES INC received a nyse_american noncompliance notice notice regarding late filing (rules 1007).
  - Exchange: nyse american
  - Notice: noncompliance notice
  - Deficiency: late filing
  - Rules: 1007
  source text: June 24, 2025, the Company received a letter (the “Extension Notice”) from the NYSE, informing the Company that the NYSE accepted the extension request, granting the Company a plan period through August 19, 2025 (the “New Cure Deadline”) to submit its delinquent reports. NYSE staff will review the Company periodically for compliance with adherence to the milestones in the plan, and if the Company does not make progress consistent with the plan during the plan period or if the Company does not complete its delinquent reports by the end of the maximum 12-month cure period on December 30, 2025, N
  evidence_url: https://www.sec.gov/Archives/edgar/data/64472/000119312525149714/0001193125-25-149714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.